AR102592A1 - Anticuerpos biespecíficos y métodos de uso en oftalmología - Google Patents
Anticuerpos biespecíficos y métodos de uso en oftalmologíaInfo
- Publication number
- AR102592A1 AR102592A1 ARP150103645A ARP150103645A AR102592A1 AR 102592 A1 AR102592 A1 AR 102592A1 AR P150103645 A ARP150103645 A AR P150103645A AR P150103645 A ARP150103645 A AR P150103645A AR 102592 A1 AR102592 A1 AR 102592A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- amino acid
- acid sequence
- sec
- variable domain
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 18
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 abstract 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 208000014245 Ocular vascular disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192517 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102592A1 true AR102592A1 (es) | 2017-03-08 |
Family
ID=51868112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103645A AR102592A1 (es) | 2014-11-10 | 2015-11-09 | Anticuerpos biespecíficos y métodos de uso en oftalmología |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10730938B2 (enExample) |
| EP (1) | EP3218399A1 (enExample) |
| JP (1) | JP2017537896A (enExample) |
| KR (1) | KR20170080584A (enExample) |
| CN (1) | CN107074941A (enExample) |
| AR (1) | AR102592A1 (enExample) |
| AU (1) | AU2015345323A1 (enExample) |
| BR (1) | BR112017009764A2 (enExample) |
| CA (1) | CA2963175A1 (enExample) |
| IL (1) | IL251128A0 (enExample) |
| MX (1) | MX2017005977A (enExample) |
| RU (1) | RU2017120360A (enExample) |
| SG (1) | SG11201703428SA (enExample) |
| TW (1) | TW201632551A (enExample) |
| WO (1) | WO2016075037A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2417156T3 (en) | 2009-04-07 | 2015-03-02 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| KR20170082594A (ko) * | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| CA2963719A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-il-1beta antibodies and methods of use |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN109863171B (zh) | 2016-08-23 | 2023-08-04 | 免疫医疗有限公司 | 抗vegf-a和抗ang2抗体及其用途 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| PH12021551470A1 (en) * | 2018-12-21 | 2022-04-11 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021198034A1 (en) * | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| CN117500828A (zh) * | 2021-06-04 | 2024-02-02 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025211874A1 (ko) * | 2024-04-04 | 2025-10-09 | 주식회사 크로스포인트테라퓨틱스 | 인간 항체 fc 변이체 포함 이중항체 및 그 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| JP2005518802A (ja) | 2002-02-28 | 2005-06-30 | イーライ・リリー・アンド・カンパニー | 抗インターロイキン−１ベータ類縁体 |
| EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
| CN1780855B (zh) | 2003-01-24 | 2011-03-30 | 应用分子进化公司 | 人IL-1β拮抗剂 |
| DE602004021901D1 (de) | 2003-01-28 | 2009-08-20 | Academisch Ziekenhuis Leiden | Aus ll-37 abgeleiteten peptidinhibitoren von toxinen |
| WO2005052002A2 (en) | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| CN101217979A (zh) | 2005-06-14 | 2008-07-09 | 安姆根有限公司 | 自缓冲蛋白制剂 |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| DK2293816T3 (da) | 2008-06-06 | 2013-02-04 | Xoma Technology Ltd | Fremgangsmåder til behandling af reumatoid arthritis |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR20110110349A (ko) | 2009-01-29 | 2011-10-06 | 아보트 러보러터리즈 | Ｉｌ-1 결합 단백질 |
| IN2012DN02634A (enExample) | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US8551487B2 (en) * | 2010-05-07 | 2013-10-08 | Xoma Technology, Ltd. | Methods for the treatment of IL-1β related conditions |
| BR112013003279A2 (pt) | 2010-08-13 | 2016-06-14 | Genentech In | “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal” |
| RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| SG10201604699VA (en) | 2010-12-21 | 2016-07-28 | Abbvie Inc | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
| JP6069312B2 (ja) | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
| BR112014032316A2 (pt) * | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
| RS62509B1 (sr) * | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| CA2883880A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| KR102467714B1 (ko) | 2012-11-08 | 2022-11-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
| EP2917237A1 (en) * | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
| PL2992012T3 (pl) * | 2013-04-29 | 2019-12-31 | F. Hoffmann-La Roche Ag | Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania |
| EA201600474A1 (ru) | 2013-12-20 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Комбинированная терапия с использованием антитела к ang2 и агониста cd40 |
| EP3094647A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| KR20170082594A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| CA2963719A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-il-1beta antibodies and methods of use |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| KR20200013231A (ko) | 2017-06-02 | 2020-02-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
-
2015
- 2015-11-06 KR KR1020177011694A patent/KR20170080584A/ko not_active Withdrawn
- 2015-11-06 WO PCT/EP2015/075879 patent/WO2016075037A1/en not_active Ceased
- 2015-11-06 BR BR112017009764A patent/BR112017009764A2/pt not_active Application Discontinuation
- 2015-11-06 RU RU2017120360A patent/RU2017120360A/ru not_active Application Discontinuation
- 2015-11-06 SG SG11201703428SA patent/SG11201703428SA/en unknown
- 2015-11-06 CN CN201580060833.XA patent/CN107074941A/zh active Pending
- 2015-11-06 CA CA2963175A patent/CA2963175A1/en not_active Abandoned
- 2015-11-06 JP JP2017525022A patent/JP2017537896A/ja active Pending
- 2015-11-06 AU AU2015345323A patent/AU2015345323A1/en not_active Abandoned
- 2015-11-06 MX MX2017005977A patent/MX2017005977A/es unknown
- 2015-11-06 EP EP15790946.6A patent/EP3218399A1/en not_active Withdrawn
- 2015-11-09 AR ARP150103645A patent/AR102592A1/es unknown
- 2015-11-09 TW TW104136909A patent/TW201632551A/zh unknown
-
2017
- 2017-03-13 IL IL251128A patent/IL251128A0/en unknown
- 2017-05-09 US US15/590,176 patent/US10730938B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3218399A1 (en) | 2017-09-20 |
| US20170240629A1 (en) | 2017-08-24 |
| CA2963175A1 (en) | 2016-05-19 |
| RU2017120360A (ru) | 2018-12-13 |
| JP2017537896A (ja) | 2017-12-21 |
| RU2017120360A3 (enExample) | 2019-10-18 |
| BR112017009764A2 (pt) | 2018-02-20 |
| WO2016075037A1 (en) | 2016-05-19 |
| MX2017005977A (es) | 2017-06-29 |
| TW201632551A (zh) | 2016-09-16 |
| IL251128A0 (en) | 2017-04-30 |
| AU2015345323A1 (en) | 2017-04-06 |
| KR20170080584A (ko) | 2017-07-10 |
| CN107074941A (zh) | 2017-08-18 |
| US10730938B2 (en) | 2020-08-04 |
| SG11201703428SA (en) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| PE20170900A1 (es) | Metodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| PE20190921A1 (es) | Anticuerpos y metodos de su utilizacion | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| PE20161210A1 (es) | Anticuerpos anti-mcam y metodos de uso asociados | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |